INCREASED C-REACTIVE PROTEIN AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES-EXPERIENCE FROM PAKISTAN
DOI:
https://doi.org/10.69723/njms.03.04.0435Keywords:
Myelodysplastic syndrome, C-reactive protein, IPSS-R, Overall survivalAbstract
OBJECTIVE : To determine the bacterial causative agent and associated risk factors responsible for sudden increase in cases of acute diarrheal disease in Rawalpindi/Islamabad Pakistan and to find the antimicrobial susceptibility pattern of isolates.
METHODOLOGY: A Cross-sectional observational study was carried out at Department of Microbiology, Army Medical College (National University of Medical Sciences) from 18th May 2022 to 30th July 2022. Case definition was defined and all stool specimens were processed according to Clinical Microbiology procedures hand book edition four. Bacterial growth was identified by biochemical reactions and was further confirmed by serology. Antimicrobial susceptibility testing was performed by Kirby Bauer disc diffusion method following Clinical and Laboratory Standards Institute M45-A-2 document.
Risk factors like age, gender, socio economic determinants, provision of safe drinking water, availability of toilets and hygiene facilities. History was evaluated through structured questionnaire after obtaining informed consent. Data was analyzed using statistical package for social sciences version 26 and correlation was determined between different risk factors and presence of disease.
RESULTS : A total of 51 patients were recruited in the study. The mean age of positive cases was 40.80 years. All isolates were identified as biotype Classical serotype Ogawa and had same antibiotic susceptibility pattern i.e. Ampicillin, Azithromycin, Chloramphenicol, Tetracycline, Doxycyline, Ciprofloxacin sensitive to except trimethoprim-sulfamethoxazole.
CONCLUSION : The organism responsible for rise in cases of acute diarrhea was Vibrio Cholera. A rise in cholera cases was associated with significant hospitalizations and mortality. With the increase rising trend of cholera cases in our hospital and Pakistan, we determined antibiotic susceptibility patterns of the Vibrio Cholerae. To overcome this threat, provision of safe drinking water, testing facilities and proper sewage should be available.
KEYWORDS : Cholera, Developing countries Outbreak, Risk factors
References
Park M. Myelodysplastic syndrome with genetic predisposition. Blood research2021;56(Suppl 1):34.
Goldberg SL, Chen E, Corral M, Guo A, Mody-Patel N, Pecora AL, Laouri M. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol2010;28(17):2847-52.
Jiang Y, Eveillard J-R, Couturier M-A, Soubise B, Chen J-M, Gao S, Basinko A, Morel F, Douet-Guilbert N, Troadec M-B. Asian population is more prone to develop high-risk myelodysplastic syndrome, concordantly with their propensity to exhibit high-risk cytogenetic aberrations. Cancers2021;13(3):481.
Heibl S, Stauder R, Pfeilstöcker M. Is myelodysplasia a consequence of normal aging? Current Oncology Reports2021;23:1-11.
Wang F, Ni J, Wu L, Wang Y, He B, Yu D. Gender disparity in the survival of patients with primary myelodysplastic syndrome. Journal of Cancer2019;10(5):1325.
Bejar R. Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica2014;99(6):956.
Volpe VO, Garcia-Manero G, Komrokji RS. SOHO State of the Art & Next Questions: Myelodysplastic Syndromes: A New Decade. Clinical Lymphoma Myeloma and Leukemia2022;22(1):1-16.
Menssen AJ, Walter MJ. Genetics of progression from MDS to secondary leukemia. Blood, The Journal of the American Society of Hematology2020;136(1):50-60.
Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood, The Journal of the American Society of Hematology2019;133(10):1039-48.
Van Etten RA. Aberrant cytokine signaling in leukemia. Oncogene2007;26(47):6738-49.
Elbaz O, Shaltout A. Implication of granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-3 (IL-3) in children with acute myeloid leukaemia (AML). Hematology2000;5(5):383-8.
Tao M, Li B, Nayini J, Andrews CB, Huang R-W, Devemy E, Song S, Venugopal P, Preisler HD. SCF, IL-1β, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine2000;12(6):699-707.
Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndromes. Cancer: Interdisciplinary International Journal of the American Cancer Society2008;113(7):1605-13.
Kornblau SM, McCue D, Singh N, Chen W, Estrov Z, Coombes KR. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood, The Journal of the American Society of Hematology2010;116(20):4251-61.
Pardanani A, Finke C, Lasho T, Al-Kali A, Begna K, Hanson C, Tefferi A. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia2012;26(4):693-9.
Baba Y, Saito B, Shimada S, Sasaki Y, Fujiwara S, Arai N, Kawaguchi Y, Kabasawa N, Tsukamoto H, Uto Y. Increased serum C-reactive protein is an adverse prognostic factor in low-risk myelodysplastic syndromes. International Journal of Hematology2021;114:441-8.
Anwar N, Arshad A, Nadeem M, Khurram S, Fatima N, Sharif S, Shan S, Shamsi T. Clinicohematological and cytogenetic profile of myelodysplastic syndromes in Pakistan-compare and contrast. Molecular Cytogenetics2017;10:1-7.
Ehsan A, Aziz M. Clinico-haematological characteristics in Pakistani patients of primary myelodysplastic syndrome according to World Health Organization classification. J Coll Physicians Surg Pak2010;20(4):232-6.
Mahmood R, Altaf C, Ahmed P, Khan SA, Malik HS. Myelodysplastic syndrome in Pakistan: Clinicohematological characteristics, cytogenetic profile, and risk stratification. Turkish Journal of Hematology2018;35(2):109.
Sultan S, Irfan SM. Adult primary myelodysplastic syndrome: experience from a tertiary care center in Pakistan. Asian Pacific Journal of Cancer Prevention2016;17(3):1535-7.
Anwar N, Memon FA, Shahid S, Shakeel M, Irfan M, Arshad A, Naz A, Ujjan ID, Shamsi T. The Dawn of next generation DNA sequencing in myelodysplastic syndromes-experience from Pakistan. BMC genomics2021;22(1):903.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, The Journal of the American Society of Hematology2016;127(20):2391-405.
Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F. Time-dependent changes in mortality and transformation risk in MDS. Blood, The Journal of the American Society of Hematology2016;128(7):902-10.
Artz AS, Wickrema A, Dinner S, Godley LA, Kocherginsky M, Odenike O, Rich ES, Stock W, Ulaszek J, Larson RA. Pre-treatment C-reactive protein (CRP) is a predictor for allogeneic hematopoietic cell transplantation outcomes. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation2008;14(11):1209.
Papageorgiou SG, Kotsianidis I, Bouchla A, Symeonidis A, Galanopoulos A, Viniou N-A, Hatzimichael E, Vassilakopoulos TP, Gogos D, Megalakaki A. Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes. Therapeutic advances in hematology2020;11:2040620720966121.
De Bel C, Gerritsen E, De Maaker G, Moolenaar A, Vossen J. C-reactive protein in the management of children with fever after allogeneic bone marrow transplantation. Infection1991;19(2):92-6.
Rothenburger M, Markewitz A, Lenz T, Kaulbach H-G, Marohl K, Kuhlmann W-D, Weinhold C. Detection of acute phase response and infection. The role of procalcitonin and C-reactive protein. 1999.
Schots R, Van Riet I, Ben Othman T, Trullemans F, De Waele M, Van Camp B, Kaufman L. An early increase in serum levels of C-reactive protein is an independent risk factor for the occurrence of major complications and 100-day transplant-related mortality after allogeneic bone marrow transplantation. Bone marrow transplantation2002;30(7):441-6.
Chen EC, Werner L, Hobbs GS, Narayan R, Amrein PC, Fathi AT, Brunner AM. Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. Leukemia & lymphoma2019.
Galili N, Marionneaux S, Lascher S, Mazumder A, Vesole D, Mumtaz M, Mehdi M, Jagannath S, Raza A. C-reactive protein (CRP) associated with higher risk patients with myelodysplastic syndromes (MDS). Journal of Clinical Oncology2008;26(15_suppl):18009-.
Qiao W, Young E, Feng C, Liu S, Jin J, Noor L, Rojas Hernandez CM, Borthakur G, Gorlova O, Afshar-Kharghan V. Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia. Experimental Hematology & Oncology2022;11(1):58.
Malcovati L, Porta MGD, Pascutto C, Invernizzi R, Boni M, Travaglino E, Passamonti F, Arcaini L, Maffioli M, Bernasconi P. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology2005;23(30):7594-603.
Shi X, Zheng Y, Xu L, Cao C, Dong B, Chen X. The inflammatory cytokine profile of myelodysplastic syndromes: a meta-analysis. Medicine2019;98(22):e15844.
Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M, Tanizawa T, Kamiyama R, Hirokawa K. Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia1997;11(12):2049-54.
Feng X, Scheinberg P, Wu CO, Samsel L, Nunez O, Prince C, Ganetzky RD, McCoy Jr JP, Maciejewski JP, Young NS. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica2011;96(4):602.
Makishima H, Yoshizato T, Yoshida K, Sekeres MA, Radivoyevitch T, Suzuki H, Przychodzen B, Nagata Y, Meggendorfer M, Sanada M. Dynamics of clonal evolution in myelodysplastic syndromes. Nature genetics2017;49(2):204-12.
Busque L, Sun M, Buscarlet M, Ayachi S, Zada YF, Provost S, Bourgoin V, Mollica L, Meisel M, Hinterleitner R. High-sensitivity C-reactive protein is associated with clonal hematopoiesis of indeterminate potential. Blood Advances2020;4(11):2430-8.
Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burtt N, Chavez A. Age-related clonal hematopoiesis associated with adverse outcomes. New England Journal of Medicine2014;371(26):2488-98.
Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, Kennedy JA, Schimmer AD, Schuh AC, Yee KW. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature2014;506(7488):328-33.
Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D. Clinical effect of point mutations in myelodysplastic syndromes. New England Journal of Medicine2011;364(26):2496-506.
Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, Fulton R, Schmidt H, Kalicki-Veizer J, O'Laughlin M. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia2011;25(7):1153-8.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Dr. Areeba Hamid, Dr. Aisha Arshad, Miss.Laraib Majeed, Mr.Muhammad Nizamuddin, Dr.Nida Anwar
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purposes. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
.png)
